标题
PD‐L1 immunohistochemistry: Clones, cutoffs, and controversies
作者
关键词
-
出版物
APMIS
Volume 130, Issue 6, Pages 295-313
出版商
Wiley
发表日期
2022-03-25
DOI
10.1111/apm.13223
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- IASLC Global Survey on PD-L1 Testing for Non-Small Cell Lung Cancer
- (2021) Mari Mino-Kenudson et al. Journal of Thoracic Oncology
- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
- (2021) Ahmet Sezer et al. LANCET
- Cytology for PD-L1 testing: A systematic review
- (2020) John R. Gosney et al. LUNG CANCER
- Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer
- (2020) Bharat Jasani et al. Diagnostic Pathology
- Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay
- (2020) Hans Juergen Grote et al. Journal of Thoracic Oncology
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- (2020) Matthew D Galsky et al. LANCET
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
- (2020) Takashi Kojima et al. JOURNAL OF CLINICAL ONCOLOGY
- How current assay approval policies are leading to unintended imprecision medicine
- (2020) Roberto Salgado et al. LANCET ONCOLOGY
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- (2020) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of KEYNOTE-010 trial
- (2019) R S Herbst et al. ANNALS OF ONCOLOGY
- A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non–Small Cell Lung Cancer
- (2019) Clive R. Taylor et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
- (2019) Yung-Jue Bang et al. Gastric Cancer
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell PD-L1 Expression in Patients with Advanced NCSLC Screened for the ATLANTIC Study
- (2019) Anne-Marie Boothman et al. Journal of Thoracic Oncology
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Impact of delayed fixation and decalcification on PD-L1 expression: a comparison of two clones
- (2019) Fabien Forest et al. VIRCHOWS ARCHIV
- Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen
- (2019) Maartje van Seijen et al. VIRCHOWS ARCHIV
- Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
- (2019) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray
- (2019) Sandra Martinez-Morilla et al. LABORATORY INVESTIGATION
- Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis
- (2019) Moritz Widmaier et al. MODERN PATHOLOGY
- PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation
- (2019) Han-Na Kim et al. VIRCHOWS ARCHIV
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
- (2018) J Adam et al. ANNALS OF ONCOLOGY
- Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas
- (2018) Eleanor Russell-Goldman et al. CANCER CYTOPATHOLOGY
- Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients
- (2018) Marius Ilie et al. CANCER CYTOPATHOLOGY
- PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
- (2018) Margarita Udall et al. Diagnostic Pathology
- Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma
- (2018) Viktor H Koelzer et al. HISTOPATHOLOGY
- Essential preanalytics in PD-L1 immunocytochemistry
- (2018) Nils A. t Hart et al. HISTOPATHOLOGY
- PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
- (2018) Enrico Munari et al. Journal of Thoracic Oncology
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- (2018) Ming Sound Tsao et al. Journal of Thoracic Oncology
- Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer
- (2018) Shona Hendry et al. Journal of Thoracic Oncology
- Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens
- (2018) Kenneth K. Sakata et al. CHEST
- Assessment of Programmed Death–Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non–Small Cell Lung Carcinoma
- (2018) Andrea Hernandez et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay
- (2018) Enrico Munari et al. CANCER CYTOPATHOLOGY
- Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer
- (2018) Elisa Capizzi et al. LUNG CANCER
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer
- (2018) Matthew P. Humphries et al. Journal of Oncology
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability
- (2017) Hans Brunnström et al. MODERN PATHOLOGY
- Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma
- (2017) Edwin R. Parra et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods
- (2017) Isaac E. Lloyd et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
- (2017) Patricia Gaule et al. JAMA Oncology
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
- (2016) Jamaal A Rehman et al. MODERN PATHOLOGY
- Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
- (2016) Andreas H Scheel et al. MODERN PATHOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now